Skip to main content

EssilorLuxottica creates Scientific Advisory Committee to accelerate the next era of innovation

EssilorLuxottica creates Scientific Advisory Committee
to accelerate the next era of innovation

Paris, France (1 December 2025) – EssilorLuxottica announced the creation of its Scientific Advisory Committee, bringing together some of the world’s most sought-after scientists and thought leaders from the converging fields of science, technology and healthcare. This initiative will reinforce the Group’s enduring scientific foundation and its mission to empower patients and consumers around the world.

The Scientific Advisory Committee will provide strategic guidance and forward-looking insights, helping to maximize EssilorLuxottica’s lead agenda. Acting as a catalyst for transformative thinking, the Advisory Committee will collaborate with a global network of leading scientific institutions and advise on new frontiers in the Group’s core areas of research, like ophthalmology and oculomics, physics and optics, audiology, AI and ethics.

The Scientific Advisory Committee unites five world-renowned experts, each recognized for their pioneering contributions and leadership in their respective domains:

  • Pr. Alain Aspect, PhD, 2022 Nobel laureate in Physics and 2010 Wolf Prize. Professor at Institut d’Optique Graduate School – Université Paris Saclay and École Polytechnique; Emeritus CNRS Senior Scientist.
  • Pr. Alessio Figalli, PhD, 2018 Fields medal laureate. Chaired Professor and Director of the Institute for Mathematics Research at ETH Zürich.
  • Pr. Sharon Kujawa, PhD, 2017 Callier prize winner. Professor of Otolaryngology – Head and Neck Surgery at Harvard Medical School; Principal Investigator at the Eaton-Peabody Laboratories, Mass Eye and Ear.
  • Pr. José-Alain Sahel, MD, 2024 Wolf prize winner. Distinguished Professor and Chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine; Emeritus at Sorbonne Université.
  • Pr. Effy Vayena, PhD. Professor of Bioethics at ETH Zürich; Visiting Lecturer at the Center for Bioethics, Harvard Medical School.

Building on EssilorLuxottica’s decades of pioneering research and technological breakthroughs, the creation of our first Scientific Advisory Committee marks a defining step in our innovation journey. Engaging with some of the most brilliant minds in science allows us to broaden our horizons, explore uncharted territories and translate knowledge into meaningful human impact. Their expert insights will guide our initiatives to advance ophthalmology, audiology, AI, neuroscience and beyond – amplifying the reach of our solutions across the life sciences. Together we’ll continue to shape the future of our industry, driving transformative progress and reaffirming our commitment to lead with purpose”, said Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO, of EssilorLuxottica.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.